臨床試験の適格基準を満たさない進行膵癌患者の治療成績 by 植田 亮
1 
 
平成28年度学位論文 
 
 
Treatment outcome of advanced pancreatic cancer patients  
who are ineligible for a clinical trial 
 
臨床試験の適格基準を満たさない進行膵癌患者の治療成績 
 
Akira Ueda, MD 
Department of Gastroenterology and Hematology, 
 Faculty of Medicine,  
University of Toyama 
 
 
富山大学大学院 医学薬学研究部（医学） 
消化器・造血器・腫瘍制御内科学 
植田 亮 
 
 
 
 
 
 
 
 
2 
 
TABLE OF CONTENTS 
 
Abstract  …………………………………………  3 
Key words  …………………………………………  3  
1. Introduction        …………………………………………  4 
2. Patients and Methods         ………………………  5 
2.1 patients         ………………………  5 
2.2 Treatment      ………………………  5 
2.3 Treatment Outcome         ………………………  6 
2.4 Statistical analysis          ………………………   6 
3. Results  …………………………………………  7 
3.1 Patient characteristics ………………………  7 
3.2 Response and survival       ………………………  7 
3.3 Adverse events       ………………………  8 
4. Discussion   …………………………………………  9 
5. Conclusion     ………………………………………… 11 
6. Disclosure  ………………………………………… 12 
7. References   ………………………………………… 13 
Table   ………………………………………… 15 
Figure          ………………………………………… 18 
 
 
 
 
 
 
 
3 
 
Abstract 
Objective: The aim of this study was to evaluate the outcome of patients with advanced 
pancreatic cancer in clinical practice, and assess whether chemotherapy provide a clinical 
benefit for patients who did not meet the eligibility criteria of the clinical trial. 
Methods: We retrospectively analyzed the medical records of 75 patients who received 
first-line chemotherapy for pancreatic cancer between April 2006 and September 2011. 
Patients were treated with gemcitabine (GEM) alone, S-1 alone or GEM plus S-1. Patients 
were divided into the clinical trial eligible group (arm eligible) or the ineligible group (arm 
ineligible). We evaluated the efficacy and the safety of chemotherapy. 
Results: 23 of 75 patients (31%) belonged to the ineligible group for the following reasons; 
20 patients had poor performance status, eight had massive ascites, one had synchronous 
malignancy, and one had icterus. The median progression free survival (PFS) was 3.5 
months, and the median overall survival (OS) was 6.7 months in all patients. In arm eligible, 
median PFS was 4.5 months, and median OS was 10.5 months. In arm ineligible, median 
PFS was 1.1 months, and median OS was 2.9 months. 
Conclusion: The outcome of the patients who did not meet the eligibility criteria was very 
poor. It is important to select the patients could benefit from either chemotherapy or optimal 
supportive care. 
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1. Introduction 
Pancreatic cancer is the fifth leading cause of cancer-related deaths in Japan.1 Despite 
improved diagnostic and therapeutic techniques, pancreatic cancer has remained a 
devastating disease with a 5% 5-year survival rate.2 The high mortality rate of pancreatic 
cancer is due to the high incidence of advanced disease at the time of diagnosis, aggressive 
clinical course and the lack of adequate systemic therapies. Gemcitabine (GEM) became the 
reference regimen for advanced pancreatic cancer after a randomized trial showed 
significant improvement in the median overall survival (OS) as compared with fluorouracil, 
although the survival gain was modest.3 FOLFIRINOX (a combination of oxaliplatin, 
irinotecan, fluorouracil, and leucovorin) and a combination of GEM and erlotinib showed a 
significant survival advantage as compared with GEM alone in patients with good 
performance status (PS), but had increased toxicity.4,5  
In the GEST (GEM and S-1 <tegafur-gimeracil-oteracil potassium> Trial) which was the 
latest phase 3 trial of GEM plus S-1 (GS) versus S-1 versus GEM, the outcome was 
relatively good; median progression free survival (PFS) ranged from 4.1 to 5.7 months, and 
median OS ranged from 8.8 to 10.1 months.6 However, chemotherapy was provided for 
patients who were eligible for the clinical trial as well as for the ineligible patients in clinical 
practice. Especially, there were few studies that evaluated the outcome of the patients who 
did not met the eligibility criteria of the clinical trial, and little information is available 
whether these patients benefit from chemotherapy. GEST was latest trial and the test drugs 
were widely-used for pancreatic cancer patients in Japan. Therefore, we analyzed treatment 
outcome in clinical practice by dividing patients based on whether they met the eligibility 
criteria of the GEST or not. 
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2. Patients and Methods 
2.1 Patients 
 The source of the study was the database of patients treated in our institution. The criteria 
for inclusion of patients were as follows: 20 years of age or older, clinically diagnosed 
pancreatic cancer with locally unresectable disease or metastatic lesions at the time of 
diagnosis or after curative resection, no prior systematic chemotherapy or radiation therapy. 
Clinical diagnosis was defined as follows; (1) histologically or cytologically diagnosed 
adenocarcinoma; (2) typical pancreas tumor by image with metastatic lesions; (3) growing 
pancreas tumor confirmed by imaging test; (4) accumulation of 18 
fluorodeoxyglucose-positron emission tomography (FDG-PET) suspecting pancreatic 
cancer.  
Patients were divided into the clinical trial eligible group (arm eligible) or the ineligible 
group (arm ineligible) according to GEST trial . Arm eligible was selected by the following 
criteria: Eastern Cooperative Oncology Group (ECOG) PS score of 0 or 1, oral intake 
possible, and adequate bone marrow (leukocyte count, >3500 per cubic millimeter; platelet 
count, >100,000 per cubic millimeter), liver function (bilirubin <2.0mg/dl; GOT/GPT 
<150U/l), and renal function (CCr >50ml/min). Exclusion criteria of arm eligible were as 
follows: a history of another major cancer, active infection, clinically significant 
cardiovascular disease, evidence of central nervous system metastases, and massive ascites. 
 
2.2 Treatment 
Patients were treated with GEM alone, S-1 alone or GS. The treatment schedule of each 
therapy was as follows: (1) GEM alone: GEM, at a dose of 1000 mg/m2, was delivered by 
30-minute intravenous infusion weekly for 3 weeks in 4-week courses. (2) S-1 alone: S-1 80 
mg/m2 from days 1 to 28, repeated every 6 weeks. (3) GS: GS consisted of GEM at a dose of 
1000 mg/m2, given as a 30-minute intravenous infusion on days 1 and 8, and oral S-1 at a 
dose of 60 mg/m2 from days 1 to 14, repeated every 3 weeks. When patients were elderly, 
had poor PS or for other reasons, the dosage of drugs was reduced by the judgment of the 
attending physician appropriately. Treatment was repeated until disease progression, the 
occurrence of unacceptable toxicity, or the patient’s refusal. 
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2.3 Treatment Outcome 
Response rate (RR) was evaluated using Response Evaluation Criteria in Solid Tumors 
(RECIST) version 1.1. Patients without measurable lesions were excluded from the analysis 
of RR. Adverse events were assessed according to the Common Terminology Criteria for 
Adverse Events (CTCAE) version 3.0. 
 
2.4 Statistical analysis 
Survival was updated on October 2012. The survival time was calculated from the date of 
treatment initiation to the day on which events were confirmed or to the last date of 
confirmation of survival. We estimated survival curves using the Kaplan-Meier method and 
compared them with the log-rank test. The unpaired chi-square test or Student’s t-test was 
used for the comparison between groups. All statistical analyses were performed by using 
JMP version 10 (SAS Institute, Cary NC), and p values of <0.05 (two-sided) were 
considered to indicate statistical significance.  
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3. Results 
3.1 Patient characteristics 
We retrospectively analyzed 75 patients who received first-line chemotherapy for pancreatic 
cancer between April 2006 and September 2011. Table 1 shows the patient characteristics. 
The median age of the 75 patients was 67 years (range 46-84), and 43 of 75 patients (57%) 
were male. Although most patients 55 (73%) had an ECOG PS of 0-1, some patients 20 
(27%) had a poor performance status. 49 patients (65%) had pancreas tail cancers and 59 
patients (79%) had metastatic lesions. 46 patients (61%) had a histologically or cytologically 
confirmed diagnosis of pancreatic cancer. 52 of 75 patients (69%) met eligibility criteria of 
arm eligible. 23 patients (31%) belonged to arm ineligible for the following reasons: 20 
patients had poor PS, eight had massive ascites, one had synchronous malignancy, and one 
had icterus. Comparing the difference in characteristics between arm eligible and arm 
ineligible, PS and number of metastatic organs were worse in arm ineligible. In the arm 
eligible, 33 patients (63%) received GEM, 14 patients (27%) were treated with GS, and 5 
patients (10%) received S-1, respectively. In the arm ineligible, 20 patients (87%) received 
GEM, 2 patients (9%) were treated with GS, and 1 patients (4%) received S-1, respectively. 
 
3.2 Response and survival 
With a median follow-up time of 6.5 months in all patients, the median PFS was 3.5 months, 
and the median OS was 6.7 months in all patients (Figure 1A). According to eligibility, the 
median PFS was 1.1 months in the arm ineligible and 4.5 months in the arm eligible 
(p<0.0001) (Figure 1B). The median OS of the arm ineligible and the arm eligible was 2.9 
months and 10.5 months (p<0.0001) (Figure 1C). In the patients received GEM, the median 
PFS was 1.1 months in the arm ineligible and 4.2 months in the arm eligible (p<0.0001) 
(Figure 1D). The median OS of the arm ineligible and the arm eligible was 2.4 months and 
10.3 months (p<0.0001) (Figure 1E). According to eligibility and treatment group, the 
response rate was 0% in the arm ineligible with GEM, 10% in the arm eligible with GEM, 
and 46% in the arm eligible with GS (Table 2). In the arm eligible, median PFS was 4.2 
months in GEM and 5.9 months in GS (GEM versus GS; p=0.77) (Figure 2A). Median OS 
was 9.6 months in GEM and 10.7 months in GS (GEM versus GS; p=0.92) (Figure 2B).  
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3.3 Adverse events 
Adverse events are summarized in Table 3. Treatment was generally well-tolerated in each 
group. The arm ineligible patients experienced higher frequencies of thrombocytopenia, 
anorexia, and fatigue than those in the arm eligible.  
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4. Discussion 
This retrospective study evaluated the efficacy and the safety of chemotherapy in patients 
with advanced pancreatic cancer in clinical practice. The median PFS was 3.5 months and 
the median OS was 6.7 months in all patients. The outcome of patients who met the 
eligibility criteria of the clinical trial was the expected results regardless of treatment; PFS 
was 4.5 months, and median OS was 10.5 months. On the other hand, the outcome of 
ineligible patients was very poor; PFS was 1.1 months, and median OS was 2.9 months. 
Treatment was generally well tolerated, and adverse events were manageable. 
Several previous studies have been reported the treatment outcome of advanced pancreatic 
cancer in clinical practice.7-12 In our study, patient characteristics such as age, sex ratio, PS, 
tumor location, and number of metastatic organs were similar to these reports in all patients. 
The efficacy and safety were also comparable to those reports in all patients. These previous 
studies identified poor prognostic factors for advanced pancreatic cancer, including a poor 
PS, an elevated level of CRP, an elevated level of CA 19-9 at the time of diagnosis, an 
advanced TNM stage, and a poor nutritional status or the presence of anemia. In our study, 
patients who could not enroll in the clinical trial on reasonable grounds because of poor 
physical condition also demonstrated poor prognostic factors. 
Generally, pancreatic cancer progresses rapidly, and a patient’s performance status often 
deteriorates rapidly. The main reasons why patients did not meet the eligibility criteria were 
poor performance status and massive ascites. These patients had aggressive disease 
progression and/or rapid deterioration of performance status regardless of treatment with 
chemotherapy. Furthermore, chemotherapy should be initiated to ineligible patients more 
carefully than eligible patients because ineligible patients may suffer from serious adverse 
effects. ASCO (American Society of Clinical Oncology) identified some key opportunities 
to improve care and reduce costs for oncology.13 One of these outlined the indication for 
chemotherapy treatment. It advised physicians not to use cancer-directed therapy for patients 
with solid tumors who have the following characteristics: low performance status (3 or 4), 
no benefit from prior evidence-based interventions, ineligibility for a clinical trial, and no 
strong evidence supporting the clinical value of further anticancer treatment. There have 
been few trials of chemotherapy in patients with poor PS. Two studies in lung cancer 
patients with poor PS shows improvement of quality of life, but median survival was very 
short, half that of patients of good PS. Neither of these studies had a control group. There are 
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no published trials of chemotherapy in patients with pancreatic cancer and poor physical 
condition. The current result also shows that these patients do not seem to benefit from 
chemotherapy, and the best practice would be to provide appropriate palliative and 
supportive care and referral to a hospice. 
On the other hand, some patients were in better physical condition in the eligible group. GS 
was administrated to the younger and healthier PS patients instead of GEM in our study. GS 
was generally well tolerated for these limited patients. More aggressive treatments such as 
FOLFIRINOX are necessary to provide and develop a survival benefit for the patients who 
have good PS and are able to tolerate toxicity.  
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5. Conclusion 
The outcomes of advanced pancreatic cancer patients who met the eligibility criteria of the 
clinical trial were similar to GEST. Chemotherapy has an equally benefit for these patients 
as clinical trials, and physicians should provide treatment aggressively for them. On the 
other hand, survival for advanced pancreatic cancer patients who did not meet the eligibility 
criteria of the clinical trial was very poor. These patients may not receive a survival benefit 
from existing chemotherapy. Therefore, it is important to select the patients could benefit 
from either chemotherapy or optimal supportive care. 
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Table 1. Patient Characteristics 
 All arm 
ineligible 
arm 
eligible p-value 
 (n=75) (n=23) (n=52) 
Age – yrs     
Median  67 73 62 
0.054 
Range 46-84 46-84 50-82 
Sex – no. (%)     
Male 43 (57) 14 (61) 29 (56) 
0.68 
Female 32 (43) 9 (39) 23 (44) 
ECOG performance status score – no. (%)     
0 11 (15) 0 (0) 11 (21) 
<0.0001 1 44 (58) 3 (13) 41 (79) 
2 20 (27) 20 (87) 0 (0) 
Pancreatic tumor location – no. (%)     
Head 26 (35) 9 (39) 17 (33) 
0.59 
Body 49 (65) 14 (61) 35 (67) 
Extent of disease – no. (%)     
Locally advanced 16 (21) 2 (9) 14 (27) 
0.076 
Distant metastases  59 (79) 21 (91) 38 (73) 
No. of metastatic sites involved – no. (%)     
1 25 (33) 4 (17) 21 (40) 
0.0070 
≧2 34 (45) 17 (74) 17 (32) 
Diagnosis – no. (%)     
Histologically 46 (61) 13 (57) 33 (63) 
0.57 
Clinically 29 (39) 10 (43) 19 (37) 
Chemotherapy – no. (%)     
Gemcitabine 53 (71) 20 (87) 33 (63) 
0.070 Gemcitabine + S-1 15 (20) 1 (4) 14 (27) 
S-1 7 (9) 2 (9) 5 (10) 
Abbreiations: ECOG, Eastern Cooperative Oncology Group; S-1, tegafur-gimeracil-oteracil 
potassium. 
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Table 2. Objective responses 
 arm ineligible 
with GEM 
arm eligible 
with GEM 
arm eligible 
with GS 
 (n=20) (n=33) (n=14) 
Could not be evaluated 12 2 1 
Response – no. (%)    
Complete response 0 (0) 0 (0) 0 (0) 
Partial response 0 (0) 3 (10) 6 (46) 
Stable disease 2 (25) 19 (61) 6 (46) 
Progressive disease 6 (75) 9 (29) 1 (8) 
    
Rate of objective response*    
No. (%) 0 (0) 3 (10) 6 (46) 
95% CI 0 0-18 19-73 
*The rate of objective response was defined as the percentage of patients who had a 
complete response or partial response. 
Abbreiations: GEM, gemcitabine; GS, gemcitabine + S-1; S-1, tegafur-gimeracil-oteracil 
potassium; CI, confidence interval. 
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Table 3. Toxicity 
 arm ineligible 
with GEM (n=20) 
arm eligible 
with GEM (n=33) 
arm eligible 
with GS (n=14) 
 All Grade 3/4 All Grade 3/4 All Grade 3/4 
 no. (%) 
Hematologic        
Leukopenia 10 (50) 4 (20) 22 (67) 6 (18) 11 (79) 2 (14) 
Neutropenia 9 (45) 5 (25) 22 (67) 6 (18) 10 (71) 2 (14) 
Anemia 15 (75) 2 (10) 25 (76) 2 (6) 11 (79) 1 (7) 
Thorombocytopenia 11 (55) 3 (15) 22 (67) 2 (6) 8 (57) 2 (14) 
Nonhematologic        
Anorexia 12 (60) 3 (15) 11 (33) 1 (3) 9 (64) 2 (14) 
Vomiting 4 (20) 0 (0) 8 (24) 0 (0) 0 (0) 0 (0) 
Constipation 6 (30) 0 (0) 18 (55) 0 (0) 6 (43) 0 (0) 
Diarrhea  0 (0) 0 (0) 4 (12) 1 (0) 3 (21) 1 (7) 
Fatigue 12 (60) 2 (10) 12 (36) 2 (6) 9 (64) 1 (7) 
Rash 4 (20) 0 (0) 3 (10) 0 (0) 6 (43) 1 (7) 
Abbreiations: GEM, gemcitabine; GS, gemcitabine + S-1; S-1, tegafur-gimeracil-oteracil 
potassium. 
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Figure 1A 
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Figure 1B 
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Figure 1C 
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Figure 1D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
Figure 1E 
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Figure 2A 
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Figure 2B 
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Figure Legends 
Figure 1 Kaplan-Meier Estimates of Progression-free Survival (PFS) and Overall Survival 
(OS) in all patients and according to eligibility for clinical trial. 
Notes: Panel A shows progression-free survival (PFS) and overall survival (OS) in all 
patients; the median was 3.5 months (gray line) and 6.7 months (black line), respectively.  
Panel B shows PFS, according to eligibility; the median was 1.1 months in arm ineligible 
(gray line) and 4.5 months in arm eligible (black line). 
Panel C shows OS, according to eligibility; the median was 2.9 months in arm ineligible 
(gray line) and 10.5 months in arm eligible (black line). 
Panel D shows PFS, according to eligibility in the patients received GEM; the median was 
1.1 months in arm ineligible (gray line) and 4.2 months in arm eligible (black line). 
Panel E shows OS, according to eligibility in the patients received GEM; the median was 2.4 
months in arm ineligible (gray line) and 10.3 months in arm eligible (black line). 
 
Figure 2 Kaplan-Meier Estimates of Progression-free Survival (PFS) and Overall Survival 
(OS) in the clinical trial eligible group (arm eligible), according to treatment group. 
Notes: Panel A shows progression-free survival (PFS); the median was 4.2 months in GEM 
(gray line) and 5.9 months in GEM + S-1 (GS) (black line). 
Panel B shows overall survival (OS); the median was 9.6 months in GEM (gray line) and 
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10.7 months in GS (black line). 
